Ruxolitinib
- Generic Name
- Ruxolitinib
- Brand Names
- Jakafi, Jakavi, Opzelura
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18N6
- CAS Number
- 941678-49-5
- Unique Ingredient Identifier
- 82S8X8XX8H
- Background
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...
- Indication
Ruxolitinib is indicated for the treatment of the following conditions:
Topical ruxolitinib is indicated for:
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
- Associated Therapies
- -
Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 10
- Registration Number
- NCT04908280
- Locations
- 🇺🇸
UR Medicine Dermatology College Town, Rochester, New York, United States
Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 40
- Registration Number
- NCT04908735
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 216
- Registration Number
- NCT04817007
- Locations
- 🇷🇴
Local Institution - 0052, Bucuresti, Cluj, Romania
🇷🇴Local Institution - 0083, Bucuresti, Romania
🇷🇴Local Institution - 0051, Cluj, Romania
Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 3
- Registration Number
- NCT04807777
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Managed Access Programs for INC424, Ruxolitinib
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04745637
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT04744116
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 128
- Registration Number
- NCT04669210
- Locations
- 🇷🇺
National Hematology Research Center, Moscow, Russian Federation
🇷🇺RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
Ruxolitinib in Thrombocythemia and Polycythemia Vera
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04644211
- Locations
- 🇺🇸
Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
- Conditions
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Constellation Pharmaceuticals
- Target Recruit Count
- 430
- Registration Number
- NCT04603495
- Locations
- 🇺🇸
Decatur Memorial Hospital Cancer Care Center of Decatur/Cancer Care Specialists of IL, Decatur, Illinois, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇲🇾Sunway Medical Centre, Petaling Jaya, Selangor, Malaysia
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
- Conditions
- Interventions
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 456
- Registration Number
- NCT04581954
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.